Pipeline of Inflammatory Bowel Disease H2 2015 Market Analysis adds ‘Inflammatory Bowel Disease Pipeline Review, H2 2015’ Market Research to its database, providing in-depth, high quality, transparent and market-driven, expert’s analysis.

This research provides comprehensive information on the therapeutic development for Inflammatory Bowel Disease, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Inflammatory Bowel Disease and special features on late-stage and discontinued projects.

The research enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Get discount on this research report at: .

This research features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The research is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by team. Drug profiles/records featured in the research undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

Scope for this research:

·         The report provides a snapshot of the global therapeutic landscape of Inflammatory Bowel Disease

·         The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

·         The report reviews key players involved in the therapeutics development for Inflammatory Bowel Disease and enlists all their major and minor projects

·         The report summarizes all the dormant and discontinued pipeline projects

·         A review of the Inflammatory Bowel Disease products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

·         Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

·         A detailed assessment of monotherapy and combination therapy pipeline projects

·         Coverage of the Inflammatory Bowel Disease pipeline on the basis of target, MoA, route of administration and molecule type

·         Latest news and deals relating related to pipeline products

Complete research on H2 Pipeline Review of ‘Inflammatory Bowel Disease’ spread across 1025 pages at .

Reasons to buy this research:

·         Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

·         Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

·         Develop strategic initiatives by understanding the focus areas of leading companies

·         Identify and understand important and diverse types of therapeutics under development for Inflammatory Bowel Disease

·         Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

·         Devise corrective measures for pipeline projects by understanding Inflammatory Bowel Disease pipeline depth and focus of Indication therapeutics

·         Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

·         Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned: 4D Pharma Plc, 4SC AG, AB Science SA, AbbVie Inc., Advinus Therapeutics Ltd., Aerpio Therapeutics, Inc., Ajinomoto Pharmaceuticals Co., Ltd., Akari Therapeutics, Plc, Alba Therapeutics Corporation, AlbireoPharma, Alfa Wassermann S.p.A, Allozyne, Inc., Altheus Therapeutics, Inc., Alvine Pharmaceuticals, Inc., Am-Pharma B.V., Amakem NV, Amgen Inc., Amorepacific Corporation, Ampio Pharmaceuticals, Inc., Amyra Biotech AG, Apogee Biotechnology Corporation, Ardelyx, Inc., Arena Pharmaceuticals, Inc., Argos Therapeutics, Inc., AskAt Inc., Astellas Pharma Inc., Atlantic Healthcare Plc, Avaxia Biologics, Inc., Axxam SpA, Basilea Pharmaceutica AG, BioAtla, LLC, BIOCAD, BioLineRx, Ltd., BioLingus AG, Bionovis SA, Biotec Pharmacon ASA, BioTherapeutics Inc., Blueberry Therapeutics Ltd, Boehringer Ingelheim GmbH, Calypso Biotech SA, Catabasis Pharmaceuticals, Inc., Celgene Corporation, Cell2B S.A. , Cellceutix Corporation, Celltrion, Inc., ChemoCentryx, Inc., ChironWells GmbH, Chong Kun Dang Pharmaceutical Corp., CLL Pharma, Commence Bio, Inc., Cosmo Pharmaceuticals S.p.A, Creabilis SA, Cytori Therapeutics, Inc., Daiichi Sankyo Company, Limited, DBV Technologies S.A., Delenex Therapeutics AG, Dr. Falk Pharma GmbH, Effimune SAS, Eisai Co., Ltd., Eli Lilly and Company, Eligo Bioscience S.A.S., Emergent BioSolutions Inc., Enceladus Pharmaceuticals BV, enGene, Inc, Enterome Bioscience SA, Enzo Biochem, Inc., Epirus Biopharmaceuticals, Inc., F. Hoffmann-La Roche Ltd., Ferring International Center S.A., FibroGen, Inc., Flexion Therapeutics, Inc., Galapagos NV, Genentech, Inc., Genfit SA, Genor BioPharma Co., Ltd., Gilead Sciences, Inc., GlaxoSmithKline Plc, Glenmark Pharmaceuticals Ltd., GlycoMar Limited, GW Pharmaceuticals Plc, iCo Therapeutics Inc., Idera Pharmaceuticals, Inc., Immune Response BioPharma, Inc., ImmusanT, Inc., Inbiopro Solutions Pvt. Ltd., InDex Pharmaceuticals AB, Innate Pharma SA, Innovate Biopharmaceuticals, Inc., Innovent Biologics, Inc., INOXIA Lifesciences GmbH, Intas Pharmaceuticals Ltd., Intrexon Corporation, Invion Limited, Jenrin Discovery, Inc., Johnson & Johnson, Jyant Technologies, Inc., Kaken Pharmaceutical Co., Ltd., Kezar Life Sciences, Inc., Kineta, Inc., Kymab Limited, Kyorin Pharmaceutical Co., Ltd., Kytogenics Pharmaceuticals, Inc., La Jolla Pharmaceutical Company, Lead Pharma Holding B.V., LIPID THERAPEUTICS GmbH, Lpath, Inc., LTT Bio-Pharma Co., Ltd., Lycera Corp., Mabion SA, Mabtech Limited, Medestea Research & Production S.p.A., Medgenics Inc., MedImmune, LLC, Merck & Co., Inc., Mesoblast Limited, MetrioPharm AG, Mitsubishi Tanabe Pharma Corporation, Momenta Pharmaceuticals, Inc., Morphotek, Inc., Mycenax Biotech Inc., Neovacs SA, Nivalis Therapeutics, Inc., Novozymes A/S, Ocata Therapeutics, Inc., Omni Bio Pharmaceutical Inc., Oncobiologics, Inc., Oncodesign SA, Opsona Therapeutics Limited, Otsuka Holdings Co., Ltd., Palatin Technologies, Inc., Pepscan Therapeutics, Pfenex Inc., Pfizer Inc., Plexxikon Inc., Pluristem Therapeutics Inc., Principia Biopharma Inc., ProtAb Ltd, Protagonist Therapeutics Inc., Protalix BioTherapeutics, Inc., Provid Pharmaceuticals, Inc., Qu Biologics Inc., Rebiotix Inc., Receptos, Inc., RedHill Biopharma Ltd., ReveraGen BioPharma, Inc., Salix Pharmaceuticals Ltd., Sandoz International GmbH, Saniona AB, Sanofi, Sareum Holdings Plc, SATT Nord, Selexys Pharmaceuticals Corporation, Seres Therapeutics, Inc., Sigmoid Pharma Limited, Sitari Pharmaceuticals, Inc., Soligenix, Inc., Spherium Biomed S.L., Stelic Institute & Co., sterna biologicals Gmbh & Co KG, Sucampo Pharmaceuticals, Inc., Swecure AB, Sylentis S.A., Synergy Pharmaceuticals, Inc., Synovo GmbH, TaiwanJ Pharmaceuticals Co., Ltd., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Limited, Therapeutic Proteins International, LLC, Therapix Biosciences Ltd, Theravance Biopharma, Inc., Tillotts Pharma AG, Tiziana, Tolerys SA, Toray Industries, Inc., Torrent Pharmaceuticals Limited, Trino Therapeutics Limited, UCB S.A., Upsher-Smith Laboratories, Inc., Ventria Bioscience, VG Life Sciences, Inc., Virobay Inc., Vitae Pharmaceuticals, Inc., vTv Therapeutics LLC, Winston Pharmaceuticals, Inc., Xbrane Bioscience AB, Zedira GmbH and Zyngenia, Inc.